Chemotherapy and cerebrovascular disease

Journal of B.U.ON.

Volumn 13, Issue 1, 2008, Pages 31-36

  Saynak, Mert ^a,b   Cosar Alas, R ^a   Yurut Caloglu, V ^a   Caloglu, M ^a   Kocak, Z ^a   Uzal, C ^a  

^a TRAKYA UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Chemotherapy; Coagulopathy; Disseminated intravascular coagulation; Embolism; Intracranial hemorrhage; Stroke

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; AMINOPHYLLINE; ANTIFUNGAL AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN III; ASPARAGINASE; BEVACIZUMAB; BLEOMYCIN; BLOOD CLOTTING FACTOR; CARMUSTINE; CISPLATIN; CYTARABINE; D DIMER; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; FRESH FROZEN PLASMA; HEPARIN; HOMOCYSTEINE; LOMUSTINE; METHOTREXATE; MITOMYCIN C; PREDNISONE; TAMOXIFEN; THYROXINE BINDING PROTEIN; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VINCRISTINE; VON WILLEBRAND FACTOR;

ANGINA PECTORIS; APHASIA; ARTERY THROMBOSIS; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; BRAIN INFARCTION; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ENCEPHALOMYELITIS; EPISTAXIS; FIBRINOLYSIS; FOLIC ACID DEFICIENCY; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART INFARCTION; HUMAN; HYPOMAGNESEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; MENTAL HEALTH; METABOLITE; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEOPLASM; NEPHROTOXICITY; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE TRANSFUSION; THROMBOEMBOLISM; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; VEIN THROMBOSIS;

ANTIBODIES, MONOCLONAL; ASPARAGINASE; CEREBROVASCULAR DISORDERS; CISPLATIN; FLUOROURACIL; HUMANS; METHOTREXATE; TAMOXIFEN;

EID: 41549156479     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Haller S, Lyrer P. Malignancy and stroke. Semin Cerebrovasc Dis Stroke 2005; 5: 47-54.
2. Chaturvedi S, Ansell J, Recht L. Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability? Stroke 1994; 25: 1215-1218.
3. Borowski A, Ghodsizad A, Gams E. Stroke as a first manifestation of ovarian cancer. J Neurooncol 2005; 71: 267-269.
4. Abayomi OK. Neck irradiation, carotid injury and its consequences. Oral Oncol 2004; 40: 872-878.
5. Doll DC, List AF, Greco FA et al. Acute vascular ischemic events after cisplatin based combination chemotherapy for germ cell tumors of the testis. Ann Intern Med 1986; 105: 48-51.
6. Geiger AM, Fischberg GM, Chen W et al. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004; 96: 1528-1536.
7. DeAngelis LM, Posner JB. Neurologic Complications. In: Holland JF, Frei E (Eds): Cancer Medicine (5th edn). Hamilton, London: BC Decker Inc, 2000, pp 2251-2270.
8. Feinberg WM, Swenson MR. Cerebrovascular complications of L-asparaginase therapy. Neurology 1988; 38: 127-133.
9. Mitchell L, Hoogendoorn H, Giles AR et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in L-asparaginase-induced antithrombin III deficiency. Blood 1994; 83: 386-391.
10. Priest JR, Ramsay NK, Steinherz PG et al. A syndrome of thrombosis and hemorrhage complicating L-asparaginase therapy for childhood acute lymphoblastic leukemia. J Pediatr 1982; 100: 984-989.
11. Pui CH, Jackson CW, Chesney CM et al. Involvement of von Willebrand factor in thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. Am J Hematol 1987; 25: 291-298.
12. Pui CH, Chesney CM, Weed J et al. Altered von Willebrand factor molecule in children with thrombosis following asparaginase-prednisone-vincristine therapy for leukemia. J Clin Oncol 1985; 3: 1266-1272.
13. El Amrani M, Heinzlef O, Debroucker T et al. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology 1998; 51: 899-901.
14. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56: 2765-2770.
15. Icli F, Karaoguz H, Dincol D et al. Severe vascular toxicity associated with cisplatin based chemotherapy. Cancer 1993; 72: 587-593.
16. Ruiz MA, Marugan I, Estelles A et al. The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients. Cancer 1989; 63: 643-648.
17. Chipperfield B, Chipperfield JR. Differences in metal content of the heart muscle in death from ischemic heart disease. Am Heart J 1978; 95: 732-737,
18. Bost GJ, Leitner SP, Atlas SA et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986; 4: 1684-1689.
19. Ito H, Okafuji T, Suzuki T. Vitamin E prevents endothelial injury associated with cisplatin injection into the superior mesenteric artery of rats. Heart Vessels 1995; 10: 178-184.
20. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984; 100: 704-713.
21. Li SH, Chen WH, Tang Y et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg 2006; 108: 150-156.
22. Yen T, Walsh J, Pejler G et al. Cisplatin-induced platelet activation requires mononuclear cells: role of GMP-140 and modulation of procoagulant activity. Br J Haematol 1993; 83: 259-269.
23. Raghavan D, Cox K, Childs A et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10: 1386-1389.
24. Gorelick PB. Stroke prevention therapy beyond antithrombotics: unifying mechanisms in ischemic stroke pathogenesis and implications for therapy. Stroke 2002; 33: 862-875.
25. Vezmar S, Becker A, Bode U et al. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92-104.
26. Bellamy MF, McDowell IF. Putative mechanisms for vascular damage by homocysteine. J Inher Metab Dis 1997; 20: 307-315.
27. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. New Engl J Med. 1998; 335: 1042-1050.
28. Quinn CT, Griener JC, Bottiglieri T et al. Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. J Clin Oncol 1997; 15: 2800-2806.
29. Atkins JN, Muss HB, Case D et al. High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol 1991; 14: 526-529.
30. Kwaan HC, Gordon LI. Thrombotic microangiopathy in the cancer patient. Acta Hematol 2001; 106: 52-54.
31. Keime-Guibert F, Napolitano M, Delattre JY. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998; 245: 695-708.
32. Katz JM, Segal AZ. Incidence and etiology of cerebrovascular disease inpatients with malignancy. Curr Atheroscler Rep 2005; 7: 280-288.
33. Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal cancer and other malignancies. Ann Pharmacother 2004; 38: 1258-1264.
34. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. J Clin Oncol 2003; 21: 3542.
35. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001; 344: 1997-2008.
36. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
37. Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
38. Joyce DE. The contribution of prothrombotic states to cancer-related stroke. Semin Cerebrovasc Dis Stroke 2002; 2: 151-158.
39. Mitchell LG, Sutor AH, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: Coagulopathy induced by disease and treatment. Semin Thromb Hemost 1995; 21: 390-401.
40. Winick NJ, Bowman WP, Kamen BA et al. Unexpected acute neurotoxicity in the treatment of children with acute lymphoblastic leukemia. J Nat Cancer Inst 1992; 84: 252-256.
41. Smith DB, Carl GF. Interactions between folates and carbamazepine or valproate in the rat. Neurology 1982; 32: 965-969.
42. Meropol NJ, Creaven PJ, Petrelli NJ et al. Seizures associated with leucovorin administration in cancer patients. J Natl Cancer Inst 1995; 87: 56-58.
43. Finkelstein Y, Zevin S, Heyd J et al. Emergency treatment of life-threatening intrathecal methotrexate overdose. Neurotoxicology 2004; 25: 407-410.
44. Bernini JC, Fort DW, Griener JC et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995; 345: 544-547.
45. Bettachi CJ, Kamen BA, Cush JJ. Post-methotrexate (MTX) CNS toxicity: symptom reduction with dextromethorphan. Arthritis Rheum 1999; 42: S236.
46. Drachtman RA, Golden CB, James SJ et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002; 19: 319-327.